Literature DB >> 12060513

Levulan: the first approved topical photosensitizer for the treatment of actinic keratosis.

E W B Jeffes1.   

Abstract

Actinic keratosis (AK) is a very common skin problem found in patients over 50 years of age, representing an in situ keratinocytic neoplasm that can progress to invasive squamous cell carcinoma of the skin. One Food and Drug Administration-approved treatment for AK of the face and scalp is photodynamic therapy (PDT) with 20% aminolevulinic acid (ALA). This advanced technology has been demonstrated in clinical trials to be effective and well tolerated by patients.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12060513     DOI： 10.1080/095466302317414663

Source DB:  PubMed          Journal:  J Dermatolog Treat        ISSN： 0954-6634            Impact factor:   3.359


  9 in total

1.  Therapeutic and aesthetic uses of photodynamic therapy part one of a five-part series: the use of photodynamic therapy in the treatment of actinic keratoses and in photorejuvenation.

Authors:  Michael H Gold
Journal:  J Clin Aesthet Dermatol       Date:  2008-07

Review 2.  [Photodynamic therapy of cutaneous epithelial malignancies. An evidence-based review].

Authors:  A Sidoroff
Journal:  Hautarzt       Date:  2007-07       Impact factor: 0.751

Review 3.  On the in vivo photochemical rate parameters for PDT reactive oxygen species modeling.

Authors:  Michele M Kim; Ashwini A Ghogare; Alexander Greer; Timothy C Zhu
Journal:  Phys Med Biol       Date:  2017-02-06       Impact factor: 3.609

4.  Photodynamic Therapy Effectively Treats Actinic Keratoses Without Pre-Illumination Incubation Time.

Authors:  Jessica Gandy; Brian Labadie; Dina Bierman; Christopher Zachary
Journal:  J Drugs Dermatol       Date:  2017-03-01       Impact factor: 2.114

5.  An insight into photodynamic therapy towards treating major dermatological conditions.

Authors:  Anuradha Dey; Gautam Singhvi; Anu Puri; Prashant Kesharwani; Sunil Kumar Dubey
Journal:  J Drug Deliv Sci Technol       Date:  2022-08-30       Impact factor: 5.062

6.  Dual-channel red/blue fluorescence dosimetry with broadband reflectance spectroscopic correction measures protoporphyrin IX production during photodynamic therapy of actinic keratosis.

Authors:  Stephen Chad Kanick; Scott C Davis; Yan Zhao; Tayyaba Hasan; Edward V Maytin; Brian W Pogue; M Shane Chapman
Journal:  J Biomed Opt       Date:  2014       Impact factor: 3.170

7.  Pre-treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-acid based photodynamic therapy.

Authors:  S C Kanick; S C Davis; Y Zhao; K L Sheehan; T Hasan; E V Maytin; B W Pogue; M S Chapman
Journal:  Photodiagnosis Photodyn Ther       Date:  2015-10-22       Impact factor: 3.631

Review 8.  Nanomaterials for photo-based diagnostic and therapeutic applications.

Authors:  Jyothi U Menon; Parth Jadeja; Pranjali Tambe; Khanh Vu; Baohong Yuan; Kytai T Nguyen
Journal:  Theranostics       Date:  2013-02-20       Impact factor: 11.556

9.  Ultrasound-triggered local anaesthesia.

Authors:  Alina Y Rwei; Juan L Paris; Bruce Wang; Weiping Wang; Christopher D Axon; María Vallet-Regí; Robert Langer; Daniel S Kohane
Journal:  Nat Biomed Eng       Date:  2017-08-09       Impact factor: 25.671
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.